Please login to the form below

Precision paediatrics: Treating patients with CAR-T

Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality

Dr Stuart Adams is among the scientists leading the quest to develop precision medicines for seriously ill paediatric patients. This includes working with an expert team at the Great Ormond Street Institute of Child Health to help embed precision medicine throughout the organisation and ensuring there is an integrated and multidisciplinaryapproach to treating childhood disease.

As Joint Lead Healthcare Scientist for Great Ormond Street Hospital (GOSH) Children National Health Service (NHS) Foundation Trust, and Principal Clinical Scientist in the Department of Haematology, Stuart is at the helm of this movement. He is part of a team using a groundbreaking chimeric antigen receptor T-cell (CAR-T) therapy, which is transforming outcomes for children who would otherwise have no treatment options left.

The therapy works by modifying T-cells to weaponise them against cancer cells. These cells play a central role in the immune system response. It’s cutting edge science and recently gained media attention due to both the impressive clinical trial results and the high cost of the treatment.

Crucially, the future success of CAR-T therapy will depend on conducting multidisciplinary tests to identify risk factors and determine the right therapy for a patient as early in the treatment pathway as possible. Here, we discuss the story behind CAR-T therapy and the steps being taken to ensure more patients can access it.

Can you outline your own work around CAR-T?

SA: CAR-T cell therapy is an innovative immunotherapy that modifies the body’s own immune T-cells to start attacking cancer cells. Immunotherapy has been around for many years, but this is the first time that the patients’ own T-cells have been taken out, genetically modified and put back in to target cancer cells.

There are a number of trials being undertaken throughout the world, but the first licensed product, Novartis’ Kymriah, is now available for the treatment of leukaemia and is live at GOSH. It’s working well, but it’s not perfect. Some patients have responded wonderfully but others unfortunately do relapse.

It’s expensive, and patient selection must improve so that each person receiving treatment benefits. You don’t want to put a child through a £250,000 therapy that is ultimately going to do them no good.

What are your goals for the treatment?

SA: The real goal is that when a patient has the diagnostic bone marrow taken, we can say whether this child will relapse or not following CAR-T therapy. The only way we’re going to get that kind of data is through a large retrospective analysis. As scientists, we’re using the data to work out which patient is most suitable for which treatment. Once you know if a patient profile does or doesn’t respond well to something, you can drill down into why and pick out the best treatment. It’s an exciting time for CAR-T therapy.

How does the current structure at GOSH help to bring cutting-edge treatment like CAR-T into play?

SA: It’s an integrated, holistic approach. One brilliant thing about Great Ormond Street is the integrated lab working, where lots of disciplines work together, so we’re able to really tailor the treatment approach for each patient.

In other places where tests happen and restructures have occurred, there is often a lack of communication between researchers and physicians. If those groups would have communicated, patients would have benefitted. That siloed approach is about as far removed from precision medicine as you can get because it’s like one big factory – it’s one size fits all for every patient.

There is clear intent at NHS England that personalised medicine is the way forward, and the realisation that researchers and physicians must be brought together to facilitate it. It’s tough, but at places like GOSH it works beautifully. It means that even if a patient belongs to a discipline that might be outside the team’s normal scope, they can still work with them. This approach can make targeted therapies like CAR-T a reality.

A good example at GOSH is in bone marrow transplants. Patients come from multiple disciplines – haematology, metabolic, gastro, immunology – then they are assessed in multidisciplinary

DOWNLOAD THE FULL ARTICLE HERE

12th July 2019

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

Fishawack Health, a new breed of global commercialization partner, fit for a post pandemic world
Our parent company, Fishawack Health has reorganized to deliver agile and innovative solutions for life-sciences companies in the face of rapidly changing markets
Blue Latitude Health
In the precision medicine era, the line between products and services is blurred
Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?
Blue Latitude Health
Understanding COVID-19 and varying responses across the globe
At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global response to the virus and to ensure we were best positioned to serve our clients during this challenging time. She shares the key learnings and why understanding the epidemiology of the disease is integral for fighting it.
Blue Latitude Health
Top 5 tips for a multi-indication product launch
Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.
Blue Latitude Health
If our patients are diverse, why are clinical trials so white?
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.
Blue Latitude Health
Engaging physicians during COVID-19
COVID-19 has drastically changed the lives of healthcare professionals. They are emotionally and physically drained and under huge amounts of pressure. They also need pharma’s help. Senior Consultant Pany Koizi outlines five principles for engaging with physicians during the pandemic.
Blue Latitude Health